세계의 반성 부비동염 시장 : 산업 규모, 점유율, 동향, 기회, 예측, 질환 표현형별, 치료 유형별, 유통 채널별, 지역별, 경쟁별(2020-2030년)

Global Chronic Rhinosinusitis Market was valued at USD 2.62 Billion in 2024 and is expected to reach USD 3.99 Billion in the forecast period with a CAGR of 7.23% through 2030. The Global Chronic Rhinosinusitis Market is a dynamic and evolving healthcare sector dedicated to addressing the prevalent and persistent condition of chronic rhinosinusitis (CRS). CRS is a chronic inflammatory disease affecting the nasal and sinus passages, leading to symptoms such as nasal congestion, facial pain, and impaired sense of smell. This market encompasses a wide range of pharmaceuticals, medical devices, and treatment modalities aimed at alleviating symptoms, reducing inflammation, and improving the overall quality of life for affected individuals.

One of the primary drivers of growth in the Global Chronic Rhinosinusitis Market is the increasing incidence of CRS worldwide. Factors such as environmental pollutants, allergies, and lifestyle changes contribute to the rising prevalence of this condition, creating a substantial patient pool seeking effective treatments. Healthcare providers and pharmaceutical companies are actively engaged in research and development efforts to introduce innovative therapies, including biologics, corticosteroids, and antibiotics, to manage CRS and provide long-term relief to patients.

Key Market Drivers

Rising Prevalence of Chronic Rhinosinusitis

Chronic Rhinosinusitis (CRS), characterized by prolonged inflammation of the nasal and sinus passages, has seen a notable increase in prevalence globally, significantly impacting the healthcare landscape. This rise is attributed to various factors, including environmental pollution, lifestyle changes, and heightened awareness leading to more frequent diagnoses.

Environmental pollution plays a substantial role in the escalating incidence of CRS. Exposure to air pollutants, particularly particulate matter (PM), has been correlated with increased CRS prevalence and severity. Studies indicate that for each unit increase in PM2.5, there is a 1.89-fold increased risk in the proportion of CRS patients requiring sinus surgery. Additionally, research has shown that long-term exposure to PM2.5 is associated with the development of CRS, underscoring the impact of environmental factors on this condition.

Key Market Challenges

High Treatment Costs

High treatment costs stand out as a significant hindrance in the Global Chronic Rhinosinusitis (CRS) Market, impacting both patients and healthcare systems alike. Chronic Rhinosinusitis, a persistent inflammatory condition of the nasal and sinus passages, requires comprehensive treatment approaches, including diagnostic tests, pharmaceuticals, surgical interventions, and long-term management. The cost associated with these aspects of care can present substantial challenges. One of the primary concerns related to high treatment costs is the financial burden it places on patients. Diagnostic procedures such as computed tomography (CT) scans and magnetic resonance imaging (MRI) can be expensive, and these costs are often not fully covered by insurance plans.

Key Market Trends

Biologic Therapies

Biologic therapies have emerged as a powerful and transformative force in boosting the Global Chronic Rhinosinusitis (CRS) Market. Chronic Rhinosinusitis, characterized by persistent inflammation of the nasal and sinus passages, has historically presented a challenging treatment landscape. However, biologic therapies, including monoclonal antibodies and other targeted drugs, have revolutionized the management of CRS and are driving significant growth in the market.

One of the key factors contributing to the success of biologic therapies is their precision in addressing the underlying inflammatory pathways and immune responses that drive CRS. These therapies are designed to specifically target and inhibit molecules or receptors involved in the inflammatory cascade, thereby reducing symptoms and improving the quality of life for CRS patients. By directly tackling the root causes of inflammation, biologics offer a highly effective and targeted approach to treatment.

Key Market Players

Lyra Therapeutics

Novartis AG

Medtronic plc

GlaxoSmithKline plc

AstraZeneca Plc

Sanofi AG

Dr. Reddy's Laboratories Ltd.

Stryker Corporation

Bayer AG

Smith & Nephew Plc

Report Scope:

In this report, the Global Chronic Rhinosinusitis Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Chronic Rhinosinusitis Market, By Disease Phenotype:

• Non-Eosinophilic Chronic Rhinosinusitis
• Eosinophilic Chronic Rhinosinusitis
• Infectious Chronic Rhinosinusitis
• Allergic Fungal Rhinosinusitis
• Others

Chronic Rhinosinusitis Market, By Treatment Type

• Medical Devices
• Drugs
• Nasal Drops
• Steroid Nasal Sprays
• Surgery
• Others

Chronic Rhinosinusitis Market, By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Chronic Rhinosinusitis Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Chronic Rhinosinusitis Market.

Available Customizations:

Global Chronic Rhinosinusitis Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Chronic Rhinosinusitis Market Outlook

• 4.1. Market Size & Forecast
  • 4.1.1. By Value
• 4.2. Market Share & Forecast
  • 4.2.1. By Disease Phenotype (Non-Eosinophilic Chronic Rhinosinusitis, Eosinophilic Chronic Rhinosinusitis, Infectious Chronic Rhinosinusitis, Allergic Fungal Rhinosinusitis, Others)
  • 4.2.2. By Treatment Type (Medical Devices, Drugs, Nasal Drops, Steroid Nasal Sprays, Surgery, Others)
  • 4.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 4.2.4. By Region
  • 4.2.5. By Company (2024)
• 4.3. Market Map
  • 4.3.1. By Disease Phenotype
  • 4.3.2. By Treatment Type
  • 4.3.3. By Distribution Channel
  • 4.3.4. By Region

5. Asia Pacific Chronic Rhinosinusitis Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Disease Phenotype
  • 5.2.2. By Treatment Type
  • 5.2.3. By Distribution Channel
  • 5.2.4. By Country
• 5.3. Asia Pacific: Country Analysis
  • 5.3.1. China Chronic Rhinosinusitis Market Outlook
    • 5.3.1.1. Market Size & Forecast
      • 5.3.1.1.1. By Value
    • 5.3.1.2. Market Share & Forecast
      • 5.3.1.2.1. By Disease Phenotype
      • 5.3.1.2.2. By Treatment Type
      • 5.3.1.2.3. By Distribution Channel
  • 5.3.2. India Chronic Rhinosinusitis Market Outlook
    • 5.3.2.1. Market Size & Forecast
      • 5.3.2.1.1. By Value
    • 5.3.2.2. Market Share & Forecast
      • 5.3.2.2.1. By Disease Phenotype
      • 5.3.2.2.2. By Treatment Type
      • 5.3.2.2.3. By Distribution Channel
  • 5.3.3. Australia Chronic Rhinosinusitis Market Outlook
    • 5.3.3.1. Market Size & Forecast
      • 5.3.3.1.1. By Value
    • 5.3.3.2. Market Share & Forecast
      • 5.3.3.2.1. By Disease Phenotype
      • 5.3.3.2.2. By Treatment Type
      • 5.3.3.2.3. By Distribution Channel
  • 5.3.4. Japan Chronic Rhinosinusitis Market Outlook
    • 5.3.4.1. Market Size & Forecast
      • 5.3.4.1.1. By Value
    • 5.3.4.2. Market Share & Forecast
      • 5.3.4.2.1. By Disease Phenotype
      • 5.3.4.2.2. By Treatment Type
      • 5.3.4.2.3. By Distribution Channel
  • 5.3.5. South Korea Chronic Rhinosinusitis Market Outlook
    • 5.3.5.1. Market Size & Forecast
      • 5.3.5.1.1. By Value
    • 5.3.5.2. Market Share & Forecast
      • 5.3.5.2.1. By Disease Phenotype
      • 5.3.5.2.2. By Treatment Type
      • 5.3.5.2.3. By Distribution Channel

6. Europe Chronic Rhinosinusitis Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Disease Phenotype
  • 6.2.2. By Treatment Type
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. Europe: Country Analysis
  • 6.3.1. France Chronic Rhinosinusitis Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Disease Phenotype
      • 6.3.1.2.2. By Treatment Type
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Germany Chronic Rhinosinusitis Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Disease Phenotype
      • 6.3.2.2.2. By Treatment Type
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Spain Chronic Rhinosinusitis Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Disease Phenotype
      • 6.3.3.2.2. By Treatment Type
      • 6.3.3.2.3. By Distribution Channel
  • 6.3.4. Italy Chronic Rhinosinusitis Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Disease Phenotype
      • 6.3.4.2.2. By Treatment Type
      • 6.3.4.2.3. By Distribution Channel
  • 6.3.5. United Kingdom Chronic Rhinosinusitis Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Disease Phenotype
      • 6.3.5.2.2. By Treatment Type
      • 6.3.5.2.3. By Distribution Channel

7. North America Chronic Rhinosinusitis Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Disease Phenotype
  • 7.2.2. By Treatment Type
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States Chronic Rhinosinusitis Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Disease Phenotype
      • 7.3.1.2.2. By Treatment Type
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. Mexico Chronic Rhinosinusitis Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Disease Phenotype
      • 7.3.2.2.2. By Treatment Type
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. Canada Chronic Rhinosinusitis Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Disease Phenotype
      • 7.3.3.2.2. By Treatment Type
      • 7.3.3.2.3. By Distribution Channel

8. South America Chronic Rhinosinusitis Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Disease Phenotype
  • 8.2.2. By Treatment Type
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. South America: Country Analysis
  • 8.3.1. Brazil Chronic Rhinosinusitis Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Disease Phenotype
      • 8.3.1.2.2. By Treatment Type
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. Argentina Chronic Rhinosinusitis Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Disease Phenotype
      • 8.3.2.2.2. By Treatment Type
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. Colombia Chronic Rhinosinusitis Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Disease Phenotype
      • 8.3.3.2.2. By Treatment Type
      • 8.3.3.2.3. By Distribution Channel

9. Middle East and Africa Chronic Rhinosinusitis Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Disease Phenotype
  • 9.2.2. By Treatment Type
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. MEA: Country Analysis
  • 9.3.1. South Africa Chronic Rhinosinusitis Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Disease Phenotype
      • 9.3.1.2.2. By Treatment Type
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. Saudi Arabia Chronic Rhinosinusitis Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Disease Phenotype
      • 9.3.2.2.2. By Treatment Type
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. UAE Chronic Rhinosinusitis Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Disease Phenotype
      • 9.3.3.2.2. By Treatment Type
      • 9.3.3.2.3. By Distribution Channel

10. Market Dynamics

• 10.1. Drivers
• 10.2. Challenges

11. Market Trends & Developments

• 11.1. Recent Developments
• 11.2. Product Launches
• 11.3. Mergers & Acquisitions

12. Global Chronic Rhinosinusitis Market: SWOT Analysis

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Product

14. Competitive Landscape

• 14.1. Lyra Therapeutics
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Current Capacity Analysis
  • 14.1.5. Financials (In case of listed)
  • 14.1.6. Recent Developments
  • 14.1.7. SWOT Analysis
• 14.2. Novartis AG
• 14.3. Medtronic plc
• 14.4. GlaxoSmithKline plc
• 14.5. AstraZeneca Plc
• 14.6. Sanofi AG
• 14.7. Dr. Reddy's Laboratories Ltd.
• 14.8. Stryker Corporation
• 14.9. Bayer AG
• 14.10.Smith & Nephew Plc

15. Strategic Recommendations

16. About Us & Disclaimer